KalVista Pharma Appoints New CMO, Elects Director
Ticker: KALV · Form: 8-K · Filed: Apr 22, 2024 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $42,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-appointment, personnel
Related Tickers: KALV
TL;DR
KalVista beefs up exec team with new CMO and board member.
AI Summary
KalVista Pharmaceuticals, Inc. announced on April 18, 2024, the appointment of Dr. Andrew Sinclair as Chief Medical Officer and the election of Dr. Sarah Schlesinger to its Board of Directors. The company also reported on its compensatory arrangements for certain officers.
Why It Matters
These executive and board changes could signal shifts in the company's strategic direction and leadership focus, potentially impacting its drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Numbers
- 0430 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
- 20240418 — Report Date (The earliest date of events reported in this 8-K filing.)
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- Dr. Andrew Sinclair (person) — Appointed Chief Medical Officer
- Dr. Sarah Schlesinger (person) — Elected to Board of Directors
- 001-36830 (company) — Commission File Number
- 20-0915291 (company) — IRS Number
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Andrew Sinclair has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Dr. Sarah Schlesinger has been elected to the Board of Directors.
What is the exact name of the company filing this report?
The exact name of the company is KalVista Pharmaceuticals, Inc.
On what date was this report filed?
This report was filed on April 22, 2024.
What is the Commission File Number for KalVista Pharmaceuticals, Inc.?
The Commission File Number for KalVista Pharmaceuticals, Inc. is 001-36830.
Filing Stats: 752 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-04-22 16:55:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
- $42,500 — common stock (ii) an annual retainer of $42,500 paid in cash and (iii) an annual award
Filing Documents
- kalv-20240418.htm (8-K) — 44KB
- kalv-ex99_1.htm (EX-99.1) — 13KB
- 0000950170-24-046481.txt ( ) — 172KB
- kalv-20240418.xsd (EX-101.SCH) — 24KB
- kalv-20240418_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On April 22, 2024, the Company issued a press release announcing Mr. Fairey's appointment to the Board, a copy of which is attached hereto as Exhibit 99.1. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press release dated April 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: April 22, 2024 By: /s/ Benjamin L. Palleiko Benjamin L. Palleiko Chief Executive Officer